The brain isn't a passive receiver of what's in the blood
For decades, clinicians have trusted a simple equation: measure lithium in the blood, and you understand what the brain is receiving. A new study from Newcastle University quietly unsettles that assumption, revealing through specialized brain imaging that the relationship between blood and brain concentrations is more nuanced than routine monitoring captures — and that how often a patient takes their pills shapes the brain's exposure in ways a single blood draw cannot fully see. The finding does not overturn current practice, but it deepens the question of why lithium rescues some patients from bipolar disorder while leaving others untouched.
- Lithium's therapeutic window is so narrow that the line between healing and harm — kidney damage, cardiac disruption, cognitive impairment — can be crossed with small miscalculations in dosing.
- Brain imaging of 41 bipolar patients revealed that once-daily dosing allows brain lithium to decline steadily across the day, while twice-daily dosing sustains more stable concentrations — a difference invisible to standard blood tests.
- The standard 12-hour blood draw used in clinical practice happens to align with brain levels, but it masks the full arc of what the brain experiences over 24 hours, leaving clinicians with an incomplete map.
- Some patients suffer lithium toxicity even within supposedly safe blood ranges, raising the urgent possibility that individual differences in how the brain absorbs the drug may explain both unexpected harm and treatment failure.
- Brain imaging remains too costly and specialized for routine use, but researchers believe it could one day identify early which patients will respond to lithium — potentially sparing months of ineffective treatment for the two-thirds who do not benefit.
Lithium is one of psychiatry's most enduring tools against bipolar disorder — reducing relapses, hospitalizations, and suicide risk in ways few medications can rival. Yet it operates within a dangerously narrow margin, where the gap between therapeutic and toxic is small enough to threaten kidneys, thyroid, heart, and cognition. Clinicians have long relied on blood tests to navigate that margin, drawing samples frequently at first, then settling into a routine of periodic monitoring.
A new study from Newcastle University challenges a foundational assumption underlying that practice: that blood levels faithfully reflect what is happening inside the brain. Researchers followed 41 adults with bipolar disorder through a single day, pairing specialized lithium MRI brain imaging with routine blood work. Half took lithium once daily; half took it twice. What emerged was a striking divergence — once-daily patients saw both brain and blood levels decline steadily across the day, while twice-daily patients experienced a morning spike followed by a more stable brain concentration over 24 hours. At the standard 12-hour monitoring point, brain and blood levels aligned. But the full daily pattern told a more complicated story.
The clinical implications remain unresolved. Once-daily dosing offers better adherence and less kidney stress; twice-daily dosing produces more even brain exposure. No one has yet shown whether those differences translate into meaningful changes in effectiveness or side effects. The study raises the question without answering it — and the researchers acknowledge that is precisely its value.
More provocatively, the findings gesture toward a deeper mystery: lithium works well for roughly one-third of patients and poorly for many others. If brain imaging could reveal individual patterns of lithium uptake early in treatment, clinicians might identify good candidates for the drug far sooner, sparing others prolonged and fruitless trials. That possibility remains speculative, and brain imaging is nowhere near replacing blood tests in clinical practice. But as one outside observer noted, the study represents an important technical advance — and in research, the right question, asked clearly, is often the necessary first step toward an answer.
Lithium remains one of psychiatry's most reliable weapons against bipolar disorder—it prevents relapse, cuts hospitalizations, and reduces suicide risk in ways few other drugs can match. Yet it operates within a dangerously narrow margin. The difference between a therapeutic dose and a toxic one is small enough that high levels can wreck kidneys, disrupt thyroid function, damage the heart, and impair cognition. Clinicians have long relied on blood tests to keep patients safe, drawing samples weekly at first, then every few months as treatment stabilizes.
But blood levels may not tell the whole story. A new study from Newcastle University challenges a foundational assumption in lithium treatment: that what shows up in the bloodstream accurately reflects what's happening in the brain. Researchers tracked 41 adults with bipolar disorder over the course of a single day, using a specialized brain imaging technique called lithium MRI alongside routine blood work. Half the participants took lithium once daily; half took it twice daily. Both groups had been on their regimen for at least a month.
What emerged was a striking divergence. In patients on once-daily dosing, both brain and blood lithium levels declined steadily throughout the day. In those taking the drug twice daily, levels spiked after the morning dose, then fell again—creating a more stable concentration in the brain over the full 24 hours. At the standard 12-hour monitoring point clinicians use in practice, brain levels tracked blood levels closely. But the underlying pattern differed sharply depending on how often patients took their pills.
This matters because there is no clinical consensus on which dosing schedule works better. Once-daily dosing offers practical advantages: better adherence, less kidney stress. Twice-daily dosing produces more even brain concentrations. Yet no one has definitively shown whether those differences in brain exposure translate into real differences in how well the drug works or what side effects patients experience. The study, the largest of its kind, raises the question without answering it—and that itself is valuable.
David Cousins, who co-authored the research, noted that some patients experience lithium toxicity even when blood levels fall within the safe therapeutic range. Understanding whether certain people absorb lithium into the brain more readily could eventually help identify who is at risk. His colleague Peter Thelwall emphasized that current clinical practice rests on an assumption: blood measurements reflect brain concentrations. The new data suggest that assumption holds at the standard testing point, but the full picture is more complex.
Neither researcher expects brain imaging to replace blood tests anytime soon. The technique remains expensive, specialized, and impractical for routine monitoring. But it opens a door to a deeper question: lithium works for roughly one-third of patients who take it, while many others see little or no benefit. If specific patterns of brain lithium uptake could predict who will respond, clinicians might identify good candidates for the drug far earlier in treatment, sparing others months of trial and error. That possibility remains speculative. For now, the study stands as what one outside expert called an important technical advance that raises important questions rather than providing definitive answers—and in research, sometimes that's exactly what's needed to move forward.
Notable Quotes
Understanding whether some people are prone to greater brain uptake could be very valuable— David Cousins, co-author, Newcastle University
We're not yet at the stage where brain imaging can guide routine clinical decisions— Philip Cowen, University of Oxford (external expert)
The Hearth Conversation Another angle on the story
Why does it matter that brain lithium levels don't match blood levels exactly?
Because clinicians make dosing decisions based entirely on blood tests. If the brain is absorbing lithium differently than the blood suggests, some patients might be getting too much or too little without anyone knowing.
But the study found that at the standard testing point, brain and blood levels did track together.
They did—which actually validates current practice. But it also revealed something unexpected: the path to that point differs dramatically depending on whether you take the drug once or twice a day.
So twice-daily dosing is better?
Not necessarily. More stable brain levels sound good in theory, but we don't know if that stability actually makes patients better or worse off. That's the honest answer.
What would change if you could predict who benefits from lithium?
Everything. Right now, a patient might spend months on lithium, suffering side effects, before realizing it won't help them. If brain imaging could identify responders upfront, you'd spare people that wait.
Why can't brain imaging replace blood tests?
Cost, mostly. And complexity. Blood tests are simple, cheap, and work. Brain imaging is a research tool. It might become useful for difficult cases, but routine clinical practice needs something faster and more accessible.
So this study doesn't change how doctors treat patients tomorrow?
Not tomorrow. But it changes what we're asking. It shows the brain isn't a passive receiver of whatever's in the blood. That's worth knowing.